Sep 06, 2023 / 03:00PM GMT
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
All right. Well, good morning, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this session with the management team from Inspire. With us, we have Rick Buchholz, the CFO; Randy Ban, Chief Commercial Officer; and Ezgi Yagci, Head of Investor Relations.
The format is going to be fireside chat. If anybody has a question, please raise your hand. So Rick, Randy and Ezgi, thanks so much for being here.
Questions and Answers:
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research AnalystSo let's start with, of course, GLP-1. There has been a lot of interest around that. Lilly is running the SURMOUNT-OSA study with tirzepatide in OSA patients. I think the study is expected to be completed, call it, late first quarter next year. I'd love to hear your general thoughts on the study and the potential implications for the market. I don
Trustpilot
